UK markets closed

Aerie Pharmaceuticals, Inc. (AERI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
15.88+0.10 (+0.63%)
As of 2:49PM EDT. Market open.
Currency in USD

Valuation measures

Market cap (intra-day) 5744.67M
Enterprise value 3761.83M
Trailing P/E N/A
Forward P/E 1-11.10
PEG ratio (5-yr expected) 10.09
Price/sales (ttm)8.68
Price/book (mrq)N/A
Enterprise value/revenue 38.88
Enterprise value/EBITDA 7-6.86

Trading information

Stock price history

Beta (5Y monthly) 0.71
52-week change 332.94%
S&P500 52-week change 333.41%
52-week high 321.30
52-week low 39.01
50-day moving average 316.15
200-day moving average 317.17

Share statistics

Avg vol (3-month) 3494.64k
Avg vol (10-day) 3297.82k
Shares outstanding 546.89M
Implied shares outstanding 6N/A
Float 45.8M
% held by insiders 12.40%
% held by institutions 1106.89%
Shares short (14 Jul 2021) 45.37M
Short ratio (14 Jul 2021) 49.39
Short % of float (14 Jul 2021) 411.73%
Short % of shares outstanding (14 Jul 2021) 411.46%
Shares short (prior month 14 Jun 2021) 46.54M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)30 Mar 2021


Profit margin -205.13%
Operating margin (ttm)-170.19%

Management effectiveness

Return on assets (ttm)-23.54%
Return on equity (ttm)-301.15%

Income statement

Revenue (ttm)85.77M
Revenue per share (ttm)1.87
Quarterly revenue growth (yoy)12.90%
Gross profit (ttm)55.5M
EBITDA -111.08M
Net income avi to common (ttm)-175.94M
Diluted EPS (ttm)-3.83
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)208.2M
Total cash per share (mrq)4.44
Total debt (mrq)230.05M
Total debt/equity (mrq)N/A
Current ratio (mrq)3.14
Book value per share (mrq)-0.22

Cash flow statement

Operating cash flow (ttm)-52.92M
Levered free cash flow (ttm)-33.42M